IPNN Stock Chart & Stats
$3384.27
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$2,448.52 - $3,384.27
Previous CloseN/A
VolumeN/A
Average Volume (3M)10.00
Market Cap
$260.59B
Enterprise Value$9.32K
Total Cash (Recent Filing)$1.53B
Total Debt (Recent Filing)$867.10M
Price to Earnings (P/E)29.5
Beta0.06
Next Earnings
Jul 30, 2026EPS Estimate
126.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.37
Shares Outstanding83,814,530
10 Day Avg. Volume31
30 Day Avg. Volume10
Financial Highlights & Ratios
PEG Ratio0.78
Price to Book (P/B)2.29
Price to Sales (P/S)2.70
P/FCF Ratio9.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ipsen News
IPNN FAQ
What was Ipsen’s price range in the past 12 months?
Ipsen lowest stock price was $2448.52 and its highest was $3384.27 in the past 12 months.
What is Ipsen’s market cap?
Ipsen’s market cap is $260.59B.
When is Ipsen’s upcoming earnings report date?
Ipsen’s upcoming earnings report date is Jul 30, 2026 which is in 4 days.
How were Ipsen’s earnings last quarter?
Ipsen released its earnings results on Feb 12, 2026. The company reported $120.028 earnings per share for the quarter, beating the consensus estimate of $110.198 by $9.83.
Is Ipsen overvalued?
According to Wall Street analysts Ipsen’s price is currently Undervalued.
Does Ipsen pay dividends?
Ipsen does not currently pay dividends.
What is Ipsen’s EPS estimate?
Ipsen’s EPS estimate is 126.01.
How many shares outstanding does Ipsen have?
Ipsen has 83,814,530 shares outstanding.
What happened to Ipsen’s price movement after its last earnings report?
Ipsen reported an EPS of $120.028 in its last earnings report, beating expectations of $110.198. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ipsen?
Currently, no hedge funds are holding shares in MX:IPNN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ipsen
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a inhibitor that is in phase III clinical trial for the treatment of second line follicular lymphoma; Tovorafenib that is in phase III clinical trial to treat first line pediatric Low-Grade Gliomas and is In phase II clinical trial for the treatment of relapsed/refractory pediatric Low-Grade Gliomas; and IPN01194 and IPN01195 that is in phase I to treat solid tumors. The company is also developing products for rare disease comprising Bylvay for the treatment of progressive familial intrahepatic cholestasis; Iqirvo, a peroxisome proliferator-activated receptor agonist to treat primary biliary cholangitis; NutropinAq, a liquid formulation of recombinant human growth hormone; Increlex, a recombinant human insulin-like growth factor; Fidrisertib that is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressive; Ritivixibat that is in phase II clinical trial to treat primary sclerosing cholangitis. In addition, it develops neuroscience products, such as Dysport that is in phase III clinical trial for the treatment of chronic and episodic migraine; and IPN10200 that is in phase II to treat aesthetic and therapeutic indications. The company has a partnership with Simcere Zaiming Pharmaceutical Co., Ltd. for the development of SIM0613, a protein expressed on varies tumor types and cancer-associated fibroblasts. The company was founded in 1929 and is headquartered in Paris, France.